Maillard reaction products in the Escherichia coli-derived therapeutic protein interferon alfacon-1.
We have recently shown that recombinant human interferon-gamma is affected by early stages of the Maillard reaction during its production in Escherichia coli. Over time, advanced glycation end products accumulated in the purified protein, accompanied with degradation, cross-linking, and a drop in the protein's biologic activity. Here, we provide further evidence for the presence of Maillard reaction products in another E. coli-derived therapeutic protein, interferon alfacon-1. These products might interfere with both treatment efficacy and patient safety.
Mironova
Roumyana
R
Department of Gene Regulations, Institute of Molecular Biology, Bulgarian Academy of Sciences, Sofia, Bulgaria. rumym@bio21.bas.bg
Sredovska
Angelina
A
Ivanov
Ivan
I
Niwa
Toshimitsu
T
D015153:Blotting, Western; D004591:Electrophoresis, Polyacrylamide Gel; D004926:Escherichia coli; D007370:Interferon Type I / Q000032:analysis* / Q000737:chemistry* / Q000627:therapeutic use; D016898:Interferon-alpha; D015416:Maillard Reaction; D011994:Recombinant Proteins / Q000032:analysis / Q000737:chemistry / Q000627:therapeutic use
D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins; C050739:interferon alfacon-1